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Background: Infectious diseases cause many molecular assemblies and pathways within 
cellular signaling networks to function aberrantly. The most effective way to treat complex, 
diseased cellular networks is to apply multiple drugs that attack the problem from many fronts. 
However, determining the optimal combination of several drugs at specific dosages to reach an 
endpoint objective is a daunting task.
Methods: In this study, we applied an experimental feedback system control (FSC) method 
and rapidly identified optimal drug combinations that inhibit herpes simplex virus-1 infection, 
by only testing less than 0.1% of the total possible drug combinations.
Results: Using antiviral efficacy as the criterion, FSC quickly identified a highly efficacious drug 
cocktail. This cocktail contained high dose ribavirin. Ribavirin, while being an effective antiviral 
drug, often induces toxic side effects that are not desirable in a therapeutic drug combination. To 
screen for less toxic drug combinations, we applied a second FSC search in cascade and used 
both high antiviral efficacy and low toxicity as criteria. Surprisingly, the new drug combination 
eliminated the need for ribavirin, but still blocked viral infection in nearly 100% of cases.
Conclusion: This cascade search provides a versatile platform for rapid discovery of new drug 
combinations that satisfy multiple criteria.
Keywords: drug combination, HSV-1, combinatorial drug optimization, feedback system 
control, FSC, drug screening
Introduction
Current drug discovery efforts have primarily focused on identifying agents that 
tackle specific preselected cellular targets.1,2 However, in most cases a single drug 
does not correct all of the aberrantly functioning pathways in a disease to produce an 
effective treatment. Drugs directed at an individual target often have limited efficacy 
and poor safety profiles due to various factors, including compensatory changes 
in cellular networks upon drug stimulation,3 redundancy,4 crosstalk,5 and off-target 
activities.6 The use of drug combinations which act on multiple targets has been 
shown to be a more effective treatment strategy and is being used more frequently.7,8 
This approach has been supported by successful clinical applications to treat various 
diseases, such as AIDS, cancer, and atherosclerosis.9–11 Often, the studies used high 
dosages of individual drugs to ensure treatment efficacy.12 Unfortunately, the high 
doses necessary to provide efficacy often come with toxic side effects. Therefore, 
treatments with a drug combination at the lowest optimal dosages will achieve the 
goal of high efficacy and low toxicity, resulting in the most desirable drug cocktail.13,14 
However, identifying the combination of effective drug   molecules, and determining 
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the proper dosage of each constitute is a challenging task. 
For example, even a small number of different drugs (six 
drugs) each tested at a few concentrations (seven dosages) 
results in 76 = 117,649 combinations. Screening all 117,649 
combinations for the most desirable combination is an enor-
mous task in terms of labor and time. Furthermore, another 
problem with combination medicine is that the highly effica-
cious drug combination may include drug(s) that are toxic 
or have side effects.
Viral infections have stood out as an interesting 
candidate for combination drug therapy. HIV, hepatitis 
C virus, and influenza infections have been shown to be 
effectively treated by combinations of antiviral drugs. 
The pathogenesis of viral infections is caused by a coor-
dinated reprogramming of cellular pathways and protein 
complexes by viral factors to favor the replication and 
spread of the virus. Within these pathways and protein 
complexes, single targets have been found that upon 
drug manipulation can disrupt viral replication. However, 
intervention against a single drug target usually results 
in the selection of escape mutants that are ineffectively 
suppressed by the single drug. The preferred method is 
to target multiple viral pathways simultaneously, so that 
the drugs target distinct steps of viral replication to more 
effectively block replication and limit the likelihood that 
a multiple drug-resistant mutant will arise.
Herpes simplex virus-1 (HSV-1) is one of the most 
pervasive infections worldwide, causing genital, skin, and 
eye infections in millions of people.15,16 Common treatments 
for HSV-1, including virus-specific drugs such as acyclovir, 
are effective but exhibit limited long-term efficacy due 
to the development of drug resistant strains. Thus, more 
effective therapeutic methods are needed to combat the 
increasing spread of drug-resistant HSV-1. Based on an 
intensive literature search, six drugs associated with anti-
viral gene regulation, viral proliferation, cell growth, and 
cell death were selected in our experiments as candidates 
for establishing a new combination drug therapy. First, the 
standard HSV-1 antiviral drug acyclovir,17 which is effec-
tive for the treatment of most herpes virus infections, acts 
as a chain terminator of DNA polymerase in virus infected 
cells. Acyclovir is also an effective control to measure 
efficacy. The second drug we included was ribavirin,18 
which has well established antiviral activity against RNA 
virus infections such as poliovirus and hepatitis C virus but 
the mechanism for antiviral activity against DNA viruses, 
such as HSV-1, remains unknown. Next, we included three 
cellular produced interferons (IFNs), IFN-α,19 IFN-β,20 
and IFN-γ,21 that have potent antiviral effects through the 
induction of cellular innate immune pathways. Finally, we 
also included tumor necrosis factor (TNF)-α,22 a cellular 
protein that induces activation of nuclear factor kappa 
B (NF-κB) and cellular death pathways. Each of these 
compounds can potentially block HSV-1 replication by 
modulating distinct viral or cellular protein complexes and 
pathways, and thus represent distinct potential therapies. 
Therefore, a combination of these drugs should be a highly 
efficacious drug therapy.
Instead of testing all possible combinations of these 
drugs at different dosages by a high-throughput screen, an 
experimental feedback system control (FSC) approach can 
identify optimal drug combinations by testing approximately 
0.1% or less of all possible combinations.23–25 Previously, 
we focused only on rapid searching for highly efficacious 
drug combinations.23–25 Here, we have successfully applied 
the FSC approach in our experiments to search for drug 
combinations that have high antiviral efficacy and then 
applied FSC in cascade to lower the doses of a toxic drug 
(ribavirin) for the treatment of HSV-1 using an in vitro 
infection model.
Methods
Algorithm
DE  algorithm  was  coded  with  MATLAB  software 
(Mathworks Inc, Natick, MA). Each drug combination was 
represented as a vector in the software. Coded dosage was 
used rather than absolute concentration. The dosages of 
16 combinations in the first iteration were chosen arbitrarily. 
The code computed the objective function value of each com-
bination, and suggested the new group of drug combinations 
to test in the following iteration.
Reagents
IFN-α, IFN-β, and IFN-γ were purchased from PBL Inter-
feron Source (Piscataway, NJ). Ribavirin and acyclovir 
were purchased from Calbiochem (San Diego, CA). TNF-α 
was purchased from R&D Systems (Minneapolis, MN). 
  Dulbecco’s Modified Eagle’s Medium (DMEM) was pur-
chased from CELLGRO (Manassas, VA) and Fetalplex from 
Gemini Bio-Products (Woodland, CA). Penicillin/strepto-
mycin and Trypsin-ethylenediaminetetraacetic acid (EDTA) 
were obtained from GIBCO (Grand Island, NY). Paraform-
aldehyde (PFA) was purchased from Electron Microscopy 
Sciences (Hatfield, PA). Phosphate buffered saline (PBS) 
was from EMD (Rockland, MA). All other plates and tubes 
were from BD Falcon (San Jose, CA).
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Cell culture
NIH 3T3 cells were grown on 15 cm plates in DMEM supple-
mented with 5% Fetalplex and 1% penicillin/streptomycin 
and kept in a 37°C incubator with 5% CO2. To propagate 
cells, we plated 107 on each 15 mm plate and split the cells 
every 24 hours. For each experimental iteration, we plated 
2 × 105 cells/well in a 24-well plate. To minimize variance 
generated from different batches of cells, the trial group and 
crossover group were tested and compared using the same 
batch of cells for each iteration.
Viral infection
HSV-1 KOS strain expressing green fluorescent protein 
(GFP) in frame with the ICP0 protein between amino acids 
104 and 105 were a gift from Dr William Halford (Southern 
Illinois University School of Medicine, Springfield, IL). The 
virus was prepared by propagation of virus on a confluent 
monolayer of Vero cells.26 Supernatants from infected cells 
were collected and centrifuged to separate cell debris. The 
cell pellet in residual medium was frozen and thawed three 
times at −80°C and 37°C, respectively. The residual super-
natant was then pooled together with the original supernatant 
and viral titers were determined by a standard plaque assay 
on Vero cell monolayers. Multiplicity of infection (MOI) of 
0.1 was used throughout except as indicated. To control MOI, 
we added cells, virus, and drug combinations at the same 
time and incubated at 37°C. After 17 hours, culture medium 
was aspirated and cells were detached with PBS-EDTA 
treatment at 37°C for 5 minutes. Detached cells were trans-
ferred to flow cytometry tubes, pelleted, and resuspended 
in 1.6% PFA and kept at 4°C until analysis. A BD FACS 
Canto II was used for flow cytometry analysis.
Results
HSV-1 infectious disease model
HSV-1 infection on an NIH 3T3 fibroblast cell line was used 
as an in vitro model system to search for new therapeutic 
drug combinations. The antiviral drugs that we have used 
in our therapeutic model include three antiviral cytokines 
(IFN-α, IFN-β, and IFN-γ), ribavirin, acyclovir, and TNF-α. 
Virus-infected cells were treated with single drugs or drug 
combinations and cultured for 16 hours. The HSV-1 strain 
used to infect the NIH 3T3 cells encodes a GFP reporter in 
infected cells, enabling flow cytometric analysis of cells to 
measure the rate and extent of infection, because the fluores-
cence intensity of GFP correlated to the presence of virus.27 
We determined efficacy of drug treatments by comparing the 
number of GFP-negative non-infected cells in the absence or 
presence of drug treatment. This value was considered the 
antiviral readout of a drug treatment.
The success of antiviral drug combinations depends on 
two essential factors: the drug combination used and the 
dose of each drug used. In the present study, seven dose 
concentrations for each of the six drugs were evaluated. 
Consequently, the total possible combinations of drugs and 
dosages are 76 = 117,649. The dosage levels were coded with 
numbers from 0 to 6, where 0 stands for a dosage of zero, 
6 is the highest dose used for that drug as reported in the 
literature, and 5 to 1 are four-fold dilutions from the highest 
dose. The absolute concentrations, as well as the antiviral 
readouts (percentage of infected cells following treatment), 
are shown in Table 1 and Figure 1A. This pilot study shows 
that ribavirin is an effective drug, inhibiting HSV-1 infec-
tion by approximately 95% at very high doses. Treatment 
with any of the IFNs or acyclovir reduced the infection rate, 
though a large percentage of cells were infected despite drug 
  treatment. In contrast, TNF-α treatment actually potentiated 
HSV-1 infection, resulting in more infected cells than the 
non-treated control. Despite the fact TNF-α enhanced the 
infection rate, it was kept in the combination drug test for 
two reasons. First, TNF-α could have an antiviral effect if 
used in combination with other drugs. Second, if TNF-α had 
no antiviral effect or enhanced HSV-1 infection, we sought to 
determine whether it would be screened out of the possible 
drug combinations by the FSC technique.
The infectious dose of HSV-1 used (MOI: number of infec-
tious virions per cell) is a critical parameter when evaluating 
the outcome of potential therapies. Using a very high MOI 
resulted in rapid cell death, but a low MOI did not sufficiently 
reflect the antiviral effectiveness of different drug combina-
tions for inhibiting HSV-1 infection. In pilot studies, we found 
that the viral infection level was a monotonic function of MOI 
and reached a plateau around MOI of 0.5 (Figure 1B). In 
general, HSV-1 infection with an MOI of 0.1 in the absence 
of any drug resulted in an infection rate of approximately 60% 
(GFP-positive cells) at 16 hours post-infection. An MOI of 
0.1 was used throughout these studies.
Table 1 Concentration of drugs (ng/mL)
IFN-α 0 0.2 0.78 3.12 12.5 50 200
IFN-β 0 0.2 0.78 3.12 12.5 50 200
IFN-γ 0 0.2 0.78 3.12 12.5 50 200
Ribavirin 0 98 390 1560 6250 2.5e4 1e5
Acyclovir 0 20 80 320 1250 5e3 2e4
TNF-α 0 0.02 0.08 0.32 1.25 5 20
Coded concentration levels 0 1 2 3 4 5 6
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The FSC platform technology
The FSC platform technology consisted of four modules. The 
first module was the input stimulations, namely, the drug 
combinations. The second module was the biocomplex 
system of interest, which in this case was the virus and host 
cell. The third module was the objective function readouts, 
which were the goals for optimization, such as efficacy, 
toxicity, drug resistance, etc. The fourth module was the 
search algorithm, which provided the next set of stimulant 
dosages for directing the biocomplex system toward the 
desired phenotype (Figure 1C).
For the FSC approach, we started with a set of drugs at 
arbitrarily chosen concentrations to stimulate the cells infected 
with HSV-1. The percentage of the host cells that become 
infected was used as the endpoint readout of the objective 
function in the third FSC module, and will most likely not be 
satisfactory in the first permutation. The fourth module of the 
FSC used a search algorithm to determine a selection of drug 
concentrations with potentially better performance, which was 
used in the next iteration of the experiment and fed back into 
the biocomplex system. Iterations of this feedback continued 
until the optimal drug combination was reached (ie, when the 
system objective function(s) became satisfactory).
The search algorithm was the module of FSC that directed 
the tested drug combinations towards an optimal treatment for 
the biocomplex system. In this study, a differential evolution 
(DE) algorithm was applied.28 DE is a parallel search algorithm 
in which several drug combinations are tested in each iteration 
of the algorithm. A diagram of the process for implementing 
DE in the HSV-1 inhibition study is shown in Figure S1.
90
80 Interferon-alpha
Interferon-beta
Interferon-gamma
Ribavirin
Acyclovir
TNF-alpha
70
60
50
40
30
20
10
0
0
1
Concentration from lowest (0) to highest (6)M OI
Single drug antiviral activity AB
P
e
r
c
e
n
t
a
g
e
 
o
f
 
i
n
f
e
c
t
e
d
 
c
e
l
l
s
P
e
r
c
e
n
t
a
g
e
 
o
f
 
v
i
r
a
l
 
i
n
f
e
c
t
i
o
n
23456
0
20
40
60
80
100
0.05 0.10 .5 12
Figure 1 Setup of the experiment. (A) Plot of single drug dosages against efficacy. (B) Plot of infection percentage against MOI. (C) Scheme of FSC: virus attempts to infect 
normal cells, while drug combinations try to inhibit virus infection. For a non-optimal drug combination, a majority of cells would become infected. More effective drug 
combinations, suggested in later iterations, lead to fewer infected cells. Iteratively, algorithm stops when optimal drug combination is reached.
Abbreviations: FSC, feedback system control; GFP, green fluorescent protein; HSV-1, herpes simplex virus-1; MOI, multiplicity of infection.
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The search for high-efficacy drug 
combinations
In the first part of the study, inhibition of viral infection was 
the sole objective function used in the FSC screening for drug 
combinations. To initiate the FSC process, 16 parallel drug 
combinations with arbitrarily chosen concentrations were 
generated using the numerical analysis software MATLAB. 
As FSC progressed, the 16 drug combinations were updated 
in such a way that the combination drug treatment reduced 
the percentage of HSV-1-infected cells. Figure 2A shows 
the average objective function value of the 16 combinations 
as the iterations progress. This value reached a plateau at 
the 8th iteration. As FSC continued, the average dosage 
levels for each of the six drugs in the 16 combinations were 
reduced, except for the dose of ribavirin (Figure 2B). At the 
12th iteration, FSC suggested a drug combination   consisting 
of 0.2 ng/mL IFN-β, 80 ng/mL acyclovir and 25 ng/mL 
  ribavirin. Treatment of HSV-1-infected cells for 16 hours with 
this drug combination resulted in less than 0.1% GFP-positive 
cells, suggesting that it completely blocked HSV-1 infection. 
This drug combination is designated DE1. For comparison, 
treatment with the highest dose of ribavirin resulted in 5% 
of cells becoming HSV-1-infected.
In order to verify the efficacy of DE1, we also tested DE1 
on a more vicious viral strain, HSV-1 strain 17. The optimal 
drug combinations DE1 and a non-optimal drug combina-
tion of (0.78, 0.78, 0.2, 0, 0, 5) ng/mL (IFN-α, IFN-β, IFN-γ, 
ribavirin, acyclovir, TNF-α) developed in the present paper 
were tested. Cells were co-treated with drug combinations 
and HSV-1 strain 17 (MOI = 1) for 1 hour, followed by two 
times wash with regular cell culture medium (DMEM with 
5% FBS and 1% Pen-Strep). The cells were then left in fresh 
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Figure 2 Apply FSC to search for high efficacy drug combinations. (A) The average objective function value in 16 drug combinations reduced as iteration moves on. (B) After 
twelve iterations, the average dosage of ribavirin in 16 combinations increased, while the average dosages of the other antivirals reduced.
Abbreviations: FSC, feedback system control; TNF, tumor necrosis factor.
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culture medium for 24 hours. Supernatant of each sample 
was then subjected to the plaque assay in order to assess the 
viral titer in the supernatant. Our results indicated that the 
optimal drug combination DE1 (optimized for KOS strain) is 
still very effective, inhibiting about ten-fold of the strain 17 
infection. Meanwhile, the non-optimal drug combination did 
not exhibit much inhibition of either KOS or strain 17. This 
positive result indicates the same trend in efficacy for two 
HSV-1 strains (data not published in this paper).
The search for high efficacy and low 
toxicity antiviral combinations  
by cascading FSC search
The drug combination DE1 includes a high dose of   ribavirin. 
However, side effects for high doses of ribavirin are a 
drawback of this drug. Ribavirin has been reported to cause 
anemia, to be teratogenic in some animal tests, and to inhibit 
DNA synthesis in a dose dependent manner.29,30 Therefore, 
we attempted to determine whether FSC can search for a drug 
combination that simultaneously satisfies two requirements: 
(1) high antiviral efficacy and (2) low toxicity (ie, lower riba-
virin dosage).
For this search we defined a new objective function, 
OF = αVi + βRc, where Vi stands for the percentage of infected 
cells after drug treatment, Rc stands for the coded dosage 
of ribavirin, from 0 to 5. α and β are called penalty factors. 
With the introduction of penalty factors, a hybrid objective 
function for the fourth module of the FSC was created with 
these multiple requirements applied to the FSC optimization 
process. The values of α and β  reflect the relative importance 
of Vi and Rc. To ensure high efficacy, we set α = 0.9 and set 
β = 0.1 to screen out drug combinations with higher dosages 
of ribavirin. Thus, the new objective function is OF = 0.9Vi + 
0.1Rc. To verify whether this addition to the cascade FSC 
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drug screening technique could direct the biocomplex 
system to satisfy this objective function for low toxicity 
and high efficacy, the same 16 initial combinations were 
applied in a second search. As FSC proceeded through the 
iterations, the average objective function value approached 
a plateau after approximately 12 iterations (Figure 3A). 
Strikingly, at the 21st iteration, the average concentration of 
ribavirin in the 16 combinations was close to 0 (Figure 3B). 
The FSC suggested a ribavirin-free combination consist-
ing of 3.12 ng/mL IFN-β, 3.12 ng/mL IFN-γ, and 80 ng/
mL   acyclovir.   Surprisingly, this ribavirin-free drug cocktail 
inhibited 95% HSV-1 infection of the treated culture. This 
combination is designated DE2 in the rest of the study.
Comparison between FSC identified 
combinations and single antiviral drugs
Both drug combinations DE1 and DE2 were able to inhibit 
viral infection by approximately 100%, which could not be 
achieved by using any of the single drugs alone. Compared 
to single drug treatment, both DE1 and DE2 offer lower 
doses of the drugs and greater antiviral efficacy (Figure 4). 
Additionally, we cultured HSV-1-infected cells for longer 
time points, ranging from 1 day to 4 days, in the presence of 
DE1 or DE2. Both DE1- and DE2-treated samples sustained 
low levels of viral infection through day 4 (Figure 5A). We 
found that treatment with the different IFNs had decreased 
efficacy as time increased and ribavirin showed a similar 
decrease in efficacy over time (Figure S2). In contrast, 
antiviral activity of acyclovir remained constant as time 
increased. To independently confirm the flow cytometry 
results for the time course experiment, the HSV-1 virus yield 
in the culture supernatants was determined by plaque assay 
of the time course. The infectious titers of the supernatants 
were consistent with the flow cytometry results, confirming 
the antiviral effect of the DE1 and DE2 drug combinations 
(Figure 5B and Figure S3).
Comparison between FSC identified 
combinations and random combinations
We next compared the drug efficacy of the FSC identified 
drug combinations with three random combinations of the 
six antiviral drugs. Both flow cytometry analysis and GFP 
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fluorescent images are shown in Figure 6. In Figure 6, both 
DE1 and DE2 treatment almost completely blocked infec-
tion, resulting in ,5% GFP-positive cells; however, there 
were 50% to 80% virus-infected cells when treated with the 
random combinations.
Discussion
This study demonstrates that the cascade FSC scheme is 
a very versatile method in identifying optimal drug com-
binations to achieve multiple desired biological endpoint 
results.23–25 In previous studies, only one objective function 
was considered, but here we show that cascade FSC can be 
used successfully to rapidly search combinations of multiple 
drugs for optimal doses to satisfy both high efficacy and 
low toxicity. In this work, we first used drug efficacy as the 
only endpoint objective criterion. In the cascade screen, we 
introduced penalty factors against high doses of ribavirin, 
and found a distinct, effective, drug combination that did 
not include ribavirin. This is important because high doses 
of ribavirin could be toxic, including possible teratogenic 
effects. Further, this study shows the flexibility of the cas-
cade FSC method in that it allows greater freedom to design 
screens for optimal drug combinations based on various 
criteria. In theory, even more parameters may be added to the 
FSC-based search for drug combinations, including degree 
of off-target effects or other important factors that determine 
the clinical significance of drug combinations.
For drugs that have no positive contribution to viral infec-
tion, such as TNF-α in the current study, each iteration of 
the FCS suggested a decreased TNF-α dose, with the dose 
eventually dropping to and remaining at zero. Together, 
these results show that the FSC method is an effective drug 
screening process.
DE1 and DE2 are both effective at blocking HSV-1 
  infection. An interesting but extremely challenging   question 
is how these drug combinations work synergistically to affect 
a group of genes, which eventually leads towards the inhibi-
tion of infection. The first step is to identify the target genes 
influenced by a single drug. Assisted by high throughput 
screening technique, the interactions among the pathways 
and mechanisms under stimulations of combinatorial drug 
can then be studied step by step. This question is actively 
pursued by many research groups including the author’s 
laboratories.
DE1 and DE2 represent two distinct drug combi-
nations that work much more efficiently at blocking 
HSV-1   infection/replication than the individual drugs alone. 
DE1 is a combination of acyclovir, ribavirin, and a low 
level of IFN-β, while DE2 is a combination of acyclovir 
and both IFN-α and IFN-β. However, acyclovir, a common 
HSV-1 antiviral, by itself does not block HSV-1 replication 
as effectively as DE1 or DE2 treatment. We attribute the 
high antiviral efficacy of DE1 and DE2 to the combinations 
acting on multiple cellular signaling networks simultane-
ously. In DE1, ribavirin is present at a concentration high 
enough to engage other unclear signaling pathways, work-
ing in concert with acyclovir and IFN-β to direct a global 
antiviral activity. In addition, these drug combinations could 
potentiate new pathways that disrupt HSV-1 replication that 
are not triggered by single drugs alone. For example, IFN-β 
and/or ribavirin could potentiate the effect of acyclovir to 
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induce apoptosis in HSV-1-infected cells. Similarly, in the 
absence of ribavirin in DE2, we suspect that the combined 
effects of IFN-α and IFN-β synergize with acyclovir to 
block HSV-1 replication. Current research in our group is 
aimed at elucidating the mechanisms of how these antivi-
ral drugs work in combination and this will likely lead to 
greater insight on HSV-1 inhibition strategies.
In conclusion, we have developed a platform for rap-
idly screening drug combinations to determine the optimal 
drug combinations and doses from a vast search space with 
multiple search parameters. The cascade FCS allowed us to 
screen for drug combinations that are highly effective against 
HSV-1 infection and potentially limit or eliminate the toxic 
effects of some drugs by lowering the dose. This will open 
new avenues into treatment of HSV-1 infection by provid-
ing drug combinations that are much more effective than 
standard acyclovir treatment. In the searches that resulted in 
combinations DE1 and DE2, the two searches started with the 
same initial 16 drug combinations, but the different objec-
tive functions operating in the cascade FSC resulted in the 
identification of two distinct, though equally effective, drug 
combinations. This is especially important as we only needed 
to test approximately 180 drug combinations, representing 
only approximately 0.1% of the 117,649 possible drug and 
dose combinations.
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Figure S1 Illustration of differential evolution (DE) search algorithm. DE is divided into four main steps, which can me summarized as production of the original drug 
combinations, mutation stage, crossover stage, and production of the new drug combinations.
Abbreviation: TNF, tumor necrosis factor.
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day 1 to day 4, while individual drugs in general lost their antiviral efficacy after day 3.
Abbreviations: ACV, acyclovir; IFN, interferon; TNF, tumor necrosis factor.
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